bioAffinity Technologies, Inc. () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1285851,
    "name": "bioAffinity Technologies, Inc.",
    "stock_name": "bioAffinity Technologies, Inc.",
    "full_name": "bioAffinity Technologies, Inc.",
    "name_url": "stocks-analysis/bioaffinity-technologies-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "1.72",
    "chg": 0.29,
    "chgp": "20.28%",
    "dir": 1,
    "prev_price": "1.43",
    "mcapval": "6.97",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2325,
    "indexname": "S&P 500",
    "isin": "US09076W1099",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "131.18 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/bioaffinity-technologies-inc-1285851-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "bioAffinity Technologies Hits New 52-Week Low at $1.91",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bioaffinity-technologies-hits-new-52-week-low-at-191-3686479",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/bioAffinityTech_priceRelatedfactors_3686479.png",
        "date": "2025-11-10 17:20:24",
        "description": "bioAffinity Technologies, Inc. has reached a new 52-week low, reflecting ongoing financial struggles with a significant decline in performance over the past year. The company, with a market capitalization of USD 7 million, faces challenges including negative cash flow and a steep drop in operating profit growth."
      },
      {
        "title": "bioAffinity Technologies Hits New 52-Week Low at $2.05",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bioaffinity-technologies-hits-new-52-week-low-at-205-3674051",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/bioAffinityTech_priceRelatedfactors_3674051.png",
        "date": "2025-11-05 16:49:42",
        "description": "bioAffinity Technologies, Inc. has reached a new 52-week low, reflecting ongoing struggles in the Pharmaceuticals & Biotechnology sector. The company has faced a decline in performance, negative operating cash flow, and weak sales, highlighting significant challenges in its financial health and market position."
      },
      {
        "title": "bioAffinity Technologies Hits 52-Week Low at $2.27 Amidst 94% Decline",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bioaffinity-technologies-hits-52-week-low-at-227-amidst-94-decline-3671528",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/bioAffinityTech_priceRelatedfactors_3671528.png",
        "date": "2025-11-04 18:00:09",
        "description": "bioAffinity Technologies, Inc. has reached a new 52-week low, reflecting ongoing challenges in the competitive Pharmaceuticals & Biotechnology sector. With a market cap of USD 7 million, the company faces significant financial hurdles, including an operating loss, negative cash flow, and a stark decline in stock performance over the past year."
      },
      {
        "title": "bioAffinity Technologies, Inc. Hits New 52-Week High of $5.24",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bioaffinity-technologies-inc-hits-new-52-week-high-of-524-3559385",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/bioAffinityTech_priceRelatedfactors_3559385.png",
        "date": "2025-09-23 15:47:37",
        "description": "bioAffinity Technologies, Inc. has achieved a new 52-week high, reflecting a significant increase in its stock performance over the past year. The company, operating in the Pharmaceuticals & Biotechnology sector, has shown strong financial metrics despite being loss-making, highlighting its potential within the microcap market."
      },
      {
        "title": "bioAffinity Technologies Hits New 52-Week High of $5.23, Marking Major Milestone",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bioaffinity-technologies-hits-new-52-week-high-of-523-marking-major-milestone-3552683",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/bioAffinityTech_priceRelatedfactors_3552683.png",
        "date": "2025-09-22 18:21:47",
        "description": "bioAffinity Technologies, Inc. has achieved a new 52-week high, reflecting a significant increase from its previous low. With a market capitalization of USD 7 million, the company demonstrates strong efficiency in generating profits, despite being loss-making. Its low debt-to-equity ratio indicates a conservative financial strategy in a competitive industry."
      },
      {
        "title": "Is bioAffinity Technologies, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-bioaffinity-technologies-inc-technically-bullish-or-bearish-3547443",
        "imagepath": "",
        "date": "2025-09-20 19:55:25",
        "description": "As of 14 August 2025, the technical trend for bioAffinity Technologies, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD is mildly bullish on a weekly basis but bearish on a monthly basis. The Bollinger Bands and KST are bearish on both weekly and monthly time frames, while the moving averages indicate a bearish trend on the daily chart. The Dow Theory shows no trend on a weekly basis and is mildly bearish on a monthly basis. However, the On-Balance Volume (OBV) is bullish on both weekly and monthly time frames.\n\nIn terms of performance, the stock has significantly underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -81.42% versus the S&P 500's 12.22%, and a one-year return of -90.71% compared to 17.14% for the index...."
      },
      {
        "title": "Is bioAffinity Technologies, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-bioaffinity-technologies-inc-overvalued-or-undervalued-3543810",
        "imagepath": "",
        "date": "2025-09-20 18:29:17",
        "description": "As of 9 February 2024, the valuation grade for bioAffinity Technologies, Inc. has moved from does not qualify to risky, indicating a significant deterioration in its financial standing. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 5.62 and negative EV to EBIT and EV to EBITDA ratios of -0.86 and -0.92, respectively. Additionally, the company's ROCE and ROE are alarmingly low at -573.01% and -676.56%, suggesting severe inefficiencies in generating returns.\n\nIn comparison to its peers, bioAffinity's valuation ratios are notably worse; for instance, Nutriband, Inc. has a P/E ratio of -11.6179, while Nephros, Inc. stands out with a very attractive P/E of 31.3944. The stark contrast in performance and valuation metrics reinforces the notion that bioAffinity is not only underperforming but is also at a higher risk compared to its industry counterparts...."
      }
    ],
    "total": 11,
    "sid": "1285851",
    "stock_news_url": "https://www.marketsmojo.com/news/bioaffinity-technologies-inc-1285851"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

bioAffinity Technologies Hits New 52-Week Low at $1.91

2025-11-10 17:20:24

bioAffinity Technologies, Inc. has reached a new 52-week low, reflecting ongoing financial struggles with a significant decline in performance over the past year. The company, with a market capitalization of USD 7 million, faces challenges including negative cash flow and a steep drop in operating profit growth.

bioAffinity Technologies Hits New 52-Week Low at $2.05

2025-11-05 16:49:42

bioAffinity Technologies, Inc. has reached a new 52-week low, reflecting ongoing struggles in the Pharmaceuticals & Biotechnology sector. The company has faced a decline in performance, negative operating cash flow, and weak sales, highlighting significant challenges in its financial health and market position.

bioAffinity Technologies Hits 52-Week Low at $2.27 Amidst 94% Decline

2025-11-04 18:00:09

bioAffinity Technologies, Inc. has reached a new 52-week low, reflecting ongoing challenges in the competitive Pharmaceuticals & Biotechnology sector. With a market cap of USD 7 million, the company faces significant financial hurdles, including an operating loss, negative cash flow, and a stark decline in stock performance over the past year.

bioAffinity Technologies, Inc. Hits New 52-Week High of $5.24

2025-09-23 15:47:37

bioAffinity Technologies, Inc. has achieved a new 52-week high, reflecting a significant increase in its stock performance over the past year. The company, operating in the Pharmaceuticals & Biotechnology sector, has shown strong financial metrics despite being loss-making, highlighting its potential within the microcap market.

bioAffinity Technologies Hits New 52-Week High of $5.23, Marking Major Milestone

2025-09-22 18:21:47

bioAffinity Technologies, Inc. has achieved a new 52-week high, reflecting a significant increase from its previous low. With a market capitalization of USD 7 million, the company demonstrates strong efficiency in generating profits, despite being loss-making. Its low debt-to-equity ratio indicates a conservative financial strategy in a competitive industry.

Is bioAffinity Technologies, Inc. technically bullish or bearish?

2025-09-20 19:55:25

As of 14 August 2025, the technical trend for bioAffinity Technologies, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD is mildly bullish on a weekly basis but bearish on a monthly basis. The Bollinger Bands and KST are bearish on both weekly and monthly time frames, while the moving averages indicate a bearish trend on the daily chart. The Dow Theory shows no trend on a weekly basis and is mildly bearish on a monthly basis. However, the On-Balance Volume (OBV) is bullish on both weekly and monthly time frames. In terms of performance, the stock has significantly underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -81.42% versus the S&P 500's 12.22%, and a one-year return of -90.71% compared to 17.14% for the index....

Is bioAffinity Technologies, Inc. overvalued or undervalued?

2025-09-20 18:29:17

As of 9 February 2024, the valuation grade for bioAffinity Technologies, Inc. has moved from does not qualify to risky, indicating a significant deterioration in its financial standing. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 5.62 and negative EV to EBIT and EV to EBITDA ratios of -0.86 and -0.92, respectively. Additionally, the company's ROCE and ROE are alarmingly low at -573.01% and -676.56%, suggesting severe inefficiencies in generating returns. In comparison to its peers, bioAffinity's valuation ratios are notably worse; for instance, Nutriband, Inc. has a P/E ratio of -11.6179, while Nephros, Inc. stands out with a very attractive P/E of 31.3944. The stark contrast in performance and valuation metrics reinforces the notion that bioAffinity is not only underperforming but is also at a higher risk compared to its industry counterparts....

View All News